Emmaus Life SciencesEMMA -7.26% 14-Day RSI is 51.68 as of Jul. 05, 2026. The stock has 6 warning signs investors should review. Among 1,423 Biotechnology companies, Emmaus Life Sciences ranks worse than 56.43% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The industry rank for Emmaus Life Sciences's 14-Day RSI or its related term are showing as below:
EMMA's 14-Day RSI is ranked worse than 56.43% of 1423
companies
in the Biotechnology industry
Industry Median: 49.99
vs EMMA: 51.68
Emmaus Life Sciences (OTCPK:EMMA) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Emmaus Life Sciences 14-Day RSI Related Terms
EMMA vs PTIX, BZYR, RMTG: 14-Day RSI Comparison
For the Biotechnology subindustry, Emmaus Life Sciences's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emmaus Life Sciences 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Emmaus Life Sciences's 14-Day RSI falls into.
Emmaus Life Sciences (OTCPK:EMMA) 14-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emmaus Life Sciences (EMMA) has a 14-Day RSI of 51.68 as of Jul. 05, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Emmaus Life Sciences and its competitors. According to the industry distribution chart, Emmaus Life Sciences ranks #803 out of 1423 companies in the Biotechnology industry, placing it in the top 56.4%.
Is Emmaus Life Sciences' 14-Day RSI too high?
Emmaus Life Sciences' current 14-Day RSI is 51.68. The Biotechnology industry median 14-Day RSI is 49.99. Emmaus Life Sciences' value of 51.68 is 3.4% above this industry median. Based on the distribution chart, Emmaus Life Sciences ranks #803 out of 1423 companies in the Biotechnology industry, which is below the industry midpoint.
How does Emmaus Life Sciences' 14-Day RSI compare to PTIX and BZYR?
According to the Biotechnology industry distribution chart, Emmaus Life Sciences ranks #803 out of 1423 companies for 14-Day RSI. This places Emmaus Life Sciences in the lower half of its industry. The industry median 14-Day RSI is 49.99. Emmaus Life Sciences' value of 51.68 is 3.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 49.99, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Emmaus Life Sciences's current 14-Day RSI of 51.68 is 3.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Emmaus Life Sciences and its competitors. For the Biotechnology industry, the median 14-Day RSI is 49.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emmaus Life Sciences's current 14-Day RSI is 51.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmaus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Emmaus Life Sciences (EMMA) is currently considered Fairly Valued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 8.5% above its estimated fair value. The current 14-Day RSI is 51.68 and 3.4% above the Biotechnology industry median of 49.99. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Emmaus Life Sciences (EMMA), the current 14-Day RSI is 51.68 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EMMA has been successfully added to your